




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Contents lists available at ScienceDirect

International Journal of Infectious Diseases

journal homepage: www.elsevier.com/locate/ijid

Short Communication

Recrudescence of Ebola virus disease outbreak in West Africa, 2014–2016

Hyojung Lee^{a,b}, Hiroshi Nishiura^{a,b,*}^a Graduate School of Medicine, Hokkaido University, Kita 15 Jo Nishi 7 Chome, Kita-ku, Sapporo-shi, Hokkaido 060-8638, Japan^b CREST, Japan Science and Technology Agency, Kawaguchi, Saitama, Japan

ARTICLE INFO

Article history:

Received 14 July 2017

Received in revised form 4 September 2017

Accepted 8 September 2017

Corresponding Editor: Eskild Petersen, Aarhus, Denmark

Keywords:

Ebola virus disease

Survivors

Sexually transmitted infections

Epidemic

Decision-making

ABSTRACT

Objectives: There have been errors in determining the end of the Ebola virus disease (EVD) epidemic when adhering to the criteria of the World Health Organization. The present study aimed to review and learn from all known recrudescence events in West Africa occurring in 2014–2016.

Methods: Background mechanisms of five erroneous declarations in Guinea, Liberia, and Sierra Leone during 2014–2016 were reviewed.

Results: Three cases of recrudescence were suspected to have been caused by sexual contact with survivors, one to be due to international migration, and one was linked to a potentially immunocompromised mother. The three sexual transmission events involving survivors—the first two in Liberia and one in Sierra Leone—required 164 days, >150 days, and approximately 180 days, respectively, from discharge of the survivors to confirmation of the recrudescence case.

Conclusions: The events of recrudescence were associated with relatively uncommon routes of transmission other than close contact during burial or care-giving, including sexual transmission, possible immunocompromise, and migration. Recognition of the sexual transmission risk among survivors could potentially involve discrimination, which may lead to under-ascertainment.

© 2017 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

The end of an outbreak must be determined objectively (Nishiura et al., 2016). For the Ebola virus disease (EVD) outbreak in West Africa from 2014 to 2016, the World Health Organization (WHO) recommended securing 42 days (World Health Organization, 2015), or twice the observed maximum incubation period, from the time at which the last case was found negative for the virus at second testing. Subsequently, the country without EVD cases would enter a period of heightened surveillance lasting 90 days to monitor for any other occurrence of infection.

As there have been errors in determining the end of an outbreak when adhering to the criteria mentioned above, it would be valuable to learn from the events of EVD recrudescence occurring in Liberia, Guinea, and Sierra Leone. This will inform wiser decision-making in the future. The present study aimed to review

all known recrudescence events in West Africa occurring during the period 2014–2016.

Materials and methods

A recrudescence event was defined as the reappearance of at least one confirmed case of EVD in a country where the end of EVD had been declared in advance. The term ‘recrudescence’ is used, because the reappearance of EVD in West Africa has been associated with persistent activity of infection arising from already infected humans. WHO reports and other sources were reviewed in an analysis of all known recrudescence events occurring from 2014 to 2016 (World Health Organization, 2016; Sheri, 2015; Farge and Giahue, 2015; Dahl et al., 2016; Dakaractu, 2016; Center for Infectious Disease Research and Policy, 2016).

In the statistical analysis, the background mechanisms of erroneous declarations of the end of an EVD outbreak in West Africa during 2014–2016 were investigated. A survey of the demographic variables of recrudescence cases was performed (i.e., age and sex), and the most likely source of infection and the dates of illness onset and confirmation were also obtained. By examining the date of confirmation of the purported last case (i.e., the case before the recrudescence case) and the date on which the outbreak

* Corresponding author at: Graduate School of Medicine, Hokkaido University, Kita 15 Jo Nishi 7 Chome, Kita-ku, Sapporo-shi, Hokkaido 060-8638, Japan. Fax: +81 11 706 7819.

E-mail address: nishiurah@med.hokudai.ac.jp (H. Nishiura).

was declared to have ended, the following were calculated: (1) the time interval between successive confirmations, (2) the number of days from burial or the second negative testing result of the last case, and (3) the number of days in heightened surveillance.

Results

A total of five cases of recrudescence were identified (Figure 1): three occurred in Liberia and one each in Guinea and Sierra Leone (World Health Organization, 2016; Sheri, 2015; Farge and Giahuyue, 2015; Dahl et al., 2016; Dakaractu, 2016; Center for Infectious Disease Research and Policy, 2016). Two were male and three were female (Table 1). One of the three cases in Liberia was caused by inter-country migration, and therefore may be better stated as recurrence rather than recrudescence (World Health Organization, 2016; Dakaractu, 2016). That case was associated with viral exposure at a funeral in Guinea (Dakaractu, 2016). Sexual transmission involving survivors was suspected for three cases (World Health Organization, 2016; Sheri, 2015; Center for Infectious Disease Research and Policy, 2016). Of these, one in Liberia was documented as linked to a survivor who had recovered 164 days before confirmation of the recrudescence case (Dahl et al., 2016). Similarly, the recrudescence female case in Sierra Leone is believed to have been due to sexual transmission (World Health Organization, 2016; Center for Infectious Disease Research and Policy, 2016). In Guinea, three probable unconfirmed deaths considered as consistent with EVD were observed in advance of the confirmed recrudescence on March 17, 2016 (World Health Organization, 2016; Dahl et al., 2016; Dakaractu, 2016). Virologically, the causative virus of the recrudescence event was demonstrated to be closely related to the virus isolated previously in the same country (Dahl et al., 2016; Dakaractu, 2016). The route of transmission in a 15-year-old male in Liberia remains unknown, but intra-household transmission during the mother's pregnancy from the immunocompromised mother to the 15-year-old boy was suspected (World Health Organization, 2016; Farge and Giahuyue, 2015).

The time interval from laboratory confirmation of the perceived last case to confirmation of the recrudescence case ranged from 101 to 140 days (Table 1). All observed intervals were longer than the mean serial interval; i.e., the time from illness onset in the primary case to that in the secondary case, estimated at 15.3 days (WHO Ebola Response Team, 2016). From the latest date of either burial or second negative test result, it took 92–122 days to confirm the cases of recrudescence – all more than double the 42-day waiting period. Recrudescence events occurred 51–79 days after the declaration of the end of the outbreak. The time lags from

declaration to recrudescence were all within the 90-day period of heightened surveillance. The three sexual transmission events involving survivors—the first two in Liberia and one in Sierra Leone—required 164 days, >150 days, and approximately 180 days, respectively, from discharge of survivors to confirmation of the recrudescence case.

Discussion

The recrudescence events were not associated with the common routes of EVD transmission, such as close contact during burials or care-giving, but rather with other routes or reasons, including sexual transmission, possible immunocompromise, and migration. While use of a 42-day waiting period posed practical difficulties from 2014 to 2016, the present exercise was not intended to criticize that fixed, transparent criterion. Even with the use of a more objective approach, including serial interval distribution (e.g., as applied for Middle East respiratory syndrome in South Korea (Nishiura et al., 2016)), this may not have sufficiently captured the involvement of sexual transmission and other reasons for recrudescence.

The need to consider the prevention of sexual transmission via survivors when declaring the end of an epidemic poses a dilemma. This is because the recognition of such a risk among survivors could potentially involve discrimination, and fear of stigma may lead to under-ascertainment.

The results of this study suggest that the supposed end of an EVD epidemic could be divided objectively into several different types. For instance, the restriction of movement for cases and exposed individuals—i.e., socially ‘costly’ interventions—could be ceased through use of a 42-day waiting period. This may not necessarily ensure a long enough waiting time for an uncommon route of infection. Meanwhile, heightened surveillance and the avoidance of risky sexual intercourse should be set at >180 days, i.e. the observed maximum in this study, echoing a study on the transmission network (Mate et al., 2015); ideally this duration should be set at 9 months considering the persistence of the virus in semen (Deen et al., 2015). These are essential to monitor and prevent recrudescence through uncommon routes of transmission. It is intended to investigate the objective determination of the outbreak in a more explicit manner using mathematical modeling techniques.

Ethical approval

Not applicable.




Figure 1. Time-line of events: declaration of Ebola-free status and of recrudescence in Liberia, Guinea, and Sierra Leone. The time at confirmation of recrudescence cases is indicated with blue diamonds; the time of illness onset is also indicated with a green diamond, if available.

Table 1
Recrudescence of Ebola virus disease in West Africa, 2014–2016.

Country	Source of infection	Age, years	Sex	Interval between successive confirmations (days) ^a	Days from burial or second negative testing result of last case ^b	Days in heightened surveillance	Ref.
Liberia	Suspected sexual intercourse	17	Male	101 (Mar 20 to Jun 29, 2015)	93	51	World Health Organization (2016), Sheri (2015), Farge and Giahuyue (2015), Dahl et al. (2016)
Liberia	Unknown, suspected bodily fluids (of pregnant mother)	15	Male	130 (Jul 12 to Nov 19, 2015)	119	77	World Health Organization (2016), Sheri (2015), Farge and Giahuyue (2015), Dahl et al. (2016)
Liberia	Migration, bodily fluids (funeral)	30	Female	133 (Nov 20, 2015 to Apr 1, 2016)	120	78	World Health Organization (2016), Sheri (2015), Farge and Giahuyue (2015), Dahl et al. (2016), Dakaractu (2016)
Guinea	Suspected sexual intercourse and under-ascertainment	37	Female	140 (Oct 29, 2015 to Mar 17, 2016)	121	79	World Health Organization (2016), Dakaractu (2016)
Sierra Leone	Suspected sexual intercourse	22	Female	123 (Sep 13, 2015 to Jan 14, 2016)	111 ^c	68	World Health Organization (2016), Center for Infectious Disease Research and Policy (2016)

^a Duration from confirmation of the last case to confirmation of the re-emerging case.

^b Duration from burial or the second negative testing result of the last case to confirmation of the re-emerging case.

^c A declaration was made on the day following the negative laboratory test and, thus, the specified date minus 42 does not equal 68 days, as in the next column to the right.

Conflict of interest

The authors declare no conflicts of interest.

Acknowledgements

HN received funding from the Japan Agency for Medical Research and Development (AMED), Japanese Society for the Promotion of Science (JSPS) KAKENHI (grant numbers 16KT0130, 16K15356, and 17H04701), Japan Science and Technology Agency (JST) CREST program (JPMJCR1413), and RISTEX program for Science of Science, Technology and Innovation Policy. HL has received financial support through the JSPS Program for Advancing Strategic International Networks to Accelerate the Circulation of Talented Researchers. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

Center for Infectious Disease Research and Policy (CIDRAP). Sierra Leone reports second new Ebola case. 2016 January. [Cited 2017 June 22]. Available from: <http://www.cidrap.umn.edu/news-perspective/2016/01/sierra-leone-reports-second-new-ebola-case>.

- Dahl BA, Kinzer MH, Raghunathan PL, Christie A, De Cock KM, Mahoney F, et al. CDC's Response to the 2014–2016 Ebola epidemic – Guinea, Liberia, and Sierra Leone. *MMWR Suppl* 2016;65:12–20.
- Dakaractu. Related Ebola cases in Guinea and Liberia. 2016 April. [Cited 2017 June 22]. Available from: http://www.dakaractu.com/Des-cas-d-Ebola-lies-en-Guinee-et-au-Liberia_a109158.html.
- Deen GF, Knust B, Broutet N, Sesay FR, Formenty P, Ross C, et al. Ebola RNA persistence in semen of Ebola virus disease survivors – preliminary report. *N Engl J Med* 2015;. doi:<http://dx.doi.org/10.1056/NEJMoa1511410> in press.
- Farge E, Giahuyue JH. Female survivor may be cause of Ebola flare-up in Liberia. Reuters; 2015 December. [Cited 2017 June 22]. Available from: <http://www.reuters.com/article/us-health-ebola-liberia-idUSKBN0U02EJ20151217>.
- Mate SE, Kugelman JR, Nyenswah TG, Ladner JT, Wiley MR, Cordier-Lassalle T, et al. Molecular evidence of sexual transmission of Ebola virus. *N Engl J Med* 2015;373:2448–54.
- Nishiura H, Miyamatsu Y, Mizumoto K. Objective determination of end of MERS outbreak, South Korea, 2015. *Emerg Infect Dis* 2016;22:146–8.
- Sheri F. Surge of Ebola in Liberia may be linked to a survivor. *The New York Times*; 2015 July. [Cited 2017 June 22]. Available from: <https://www.nytimes.com/07/10/world/africa/surge-of-ebola-in-liberia-is-tracked-to-a-survivor.html>.
- WHO Ebola Response Team. After Ebola in West Africa – unpredictable risks, preventable epidemics. *N Engl J Med* 2016;375:587–96.
- World Health Organization. Criteria for declaring the end of the Ebola outbreak in Guinea, Liberia or Sierra Leone. Geneva: World Health Organization; 2015 [Cited 2017 September 04]. Available from: <http://www.who.int/csr/disease/ebola/declaration-ebola-end/en/>.
- World Health Organization. Ebola situation report. Geneva: World Health Organization; 2016 [Cited 2017 June 22]. Available from: <http://www.who.int/csr/disease/ebola/situation-reports/archive/en/>.